This page shows the latest Zaltrap news and features for those working in and with pharma, biotech and healthcare.
Saltz has been a vocal critic of cancer drug pricing for some time, and was one of the architects of MSKCC's decision three years ago not to prescribe Zaltrap ... Zaltrap was also turned down by the UK's National Institute for Health and Care Excellence
Sanofi's Zaltrap is one of several drugs to be delisted from England's Cancer Drugs Fund. ... cancer. In the past 18 months there have been 1, 154 and 707 requests submitted to the CDF for Zaltrap and Jevtana respectively.
Prostate cancer. Zaltrap (aflibercept). Colorectal cancer. Takeda. Adcetris (brentuximab vedotin). Lymphoma (3 indications). .
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
Afinitor (everolimus). Novartis. 1, 033. Halaven (eribulin). Eisai. 791. Zaltrap (aflibercept).
Recent industry news includes two stories of new products (Sanofi's Zaltrap and Bayer's Xofigo) struggling to get market access.
More from news
Approximately 3 fully matching, plus 12 partially matching documents found.
Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...